Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Dec 08, 2022 8:26am
153 Views
Post# 35158477

RE:RE:TH-1902 pause is no reason to blame management

RE:RE:TH-1902 pause is no reason to blame managementFrom what I have been told from those who have spoken to management, TH did not hear they had to pause the trial until mid-day on last Thursday. My guess is the doctor at MD Anderson made that call and TH may have been surprised by it, or at least by the timing of it. I would also guess, they knew they had enrollment issues that were likely related to efficacy not being good enough. Perhaps they had some better efficacy indications early on that later waned which is why we went from the key to unlock cancer to de-emphasizing cancer on the Q3 call? Alternatively, Paul was in marketing mode in September and the board forced him to stop using such optimistic language in October. 

I am sure these guesses don't capture the truth of the matter but may be in the ballpark. 



Adonis wrote: So Why paul told some weeks early # we have the key of cancer # just after that the disaster happened..


<< Previous
Bullboard Posts
Next >>